BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35043976)

  • 1. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack.
    Fang Y; Liu W; Tang Z; Ji X; Zhou Y; Song S; Tian M; Tao C; Huang R; Zhu G; Jiang X; Gao J; Qu W; Wang H; Zhou P; Wu X; Jin L; Sun H; Ding Z; Peng Y; Zhao S; Zhou J; Fan J; Xu W; Shi Y
    Hepatology; 2023 Jan; 77(1):109-123. PubMed ID: 35043976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
    Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted inhibition of MCT4 disrupts intracellular pH homeostasis and confers self-regulated apoptosis on hepatocellular carcinoma.
    Zhao Y; Li W; Li M; Hu Y; Zhang H; Song G; Yang L; Cai K; Luo Z
    Exp Cell Res; 2019 Nov; 384(1):111591. PubMed ID: 31479685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.
    Todenhöfer T; Seiler R; Stewart C; Moskalev I; Gao J; Ladhar S; Kamjabi A; Al Nakouzi N; Hayashi T; Choi S; Wang Y; Frees S; Daugaard M; Oo HZ; Fisel P; Schwab M; Schaeffeler E; Douglas J; Hennenlotter J; Bedke J; Gibb EA; Fazli L; Stenzl A; Black PC
    Mol Cancer Ther; 2018 Dec; 17(12):2746-2755. PubMed ID: 30262589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l-lactate transport in the hepatocellular carcinoma cell line.
    Mukai Y; Yamaguchi A; Sakuma T; Nadai T; Furugen A; Narumi K; Kobayashi M
    Biopharm Drug Dispos; 2022 Oct; 43(5):183-191. PubMed ID: 36104287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma.
    Ohno A; Yorita K; Haruyama Y; Kondo K; Kato A; Ohtomo T; Kawaguchi M; Marutuska K; Chijiiwa K; Kataoka H
    Liver Int; 2014 Jul; 34(6):942-52. PubMed ID: 24433439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments.
    Contreras-Baeza Y; Sandoval PY; Alarcón R; Galaz A; Cortés-Molina F; Alegría K; Baeza-Lehnert F; Arce-Molina R; Guequén A; Flores CA; San Martín A; Barros LF
    J Biol Chem; 2019 Dec; 294(52):20135-20147. PubMed ID: 31719150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas.
    Yorita K; Ohno A; Nishida T; Kondo K; Ohtomo T; Kataoka H
    BMC Res Notes; 2019 Nov; 12(1):741. PubMed ID: 31706332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCT4 blockade increases the efficacy of immune checkpoint blockade.
    Babl N; Decking SM; Voll F; Althammer M; Sala-Hojman A; Ferretti R; Korf C; Schmidl C; Schmidleithner L; Nerb B; Matos C; Koehl GE; Siska P; Bruss C; Kellermeier F; Dettmer K; Oefner PJ; Wichland M; Ugele I; Bohr C; Herr W; Ramaswamy S; Heinrich T; Herhaus C; Kreutz M; Renner K
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37880183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma.
    Long Y; Gao Z; Hu X; Xiang F; Wu Z; Zhang J; Han X; Yin L; Qin J; Lan L; Yin F; Wang Y
    Cancer Med; 2018 Sep; 7(9):4690-4700. PubMed ID: 30051648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of Monocarboxylate Transporter 4 (MCT4) expression in breast cancer prognosis and immune infiltration via integrated bioinformatics analysis.
    Yuan C; Zhang J; Lou J; Wang S; Jiang Y; Wu F; Wang S
    Bioengineered; 2021 Dec; 12(1):3850-3863. PubMed ID: 34269158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy.
    Chen HL; OuYang HY; Le Y; Jiang P; Tang H; Yu ZS; He MK; Tang YQ; Shi M
    Cancer Med; 2018 Nov; 7(11):5339-5350. PubMed ID: 30306706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocarboxylate transporter 4, associated with the acidification of synovial fluid, is a novel therapeutic target for inflammatory arthritis.
    Fujii W; Kawahito Y; Nagahara H; Kukida Y; Seno T; Yamamoto A; Kohno M; Oda R; Taniguchi D; Fujiwara H; Ejima A; Kishida T; Mazda O; Ashihara E
    Arthritis Rheumatol; 2015 Nov; 67(11):2888-96. PubMed ID: 26213210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner.
    Lim KS; Lim KJ; Price AC; Orr BA; Eberhart CG; Bar EE
    Oncogene; 2014 Aug; 33(35):4433-41. PubMed ID: 24077291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma.
    Zhao H; Chen Y; Liao YP; Chen HM; Yang QH; Xiao Y; Luo J; Chen ZZ; Yi L; Hu GY
    Clin Exp Med; 2023 Feb; 23(1):55-64. PubMed ID: 35239073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.
    Lee JY; Lee I; Chang WJ; Ahn SM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Cho JH; Kim SY; Kim KM; Lee S; Kim ST; Park SH; Lee J; Park JO; Park YS; Lim HY; Kang WK
    Oncotarget; 2016 Jul; 7(28):43492-43503. PubMed ID: 27224918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.
    Kim HK; Lee I; Bang H; Kim HC; Lee WY; Yun SH; Lee J; Lee SJ; Park YS; Kim KM; Kang WK
    Mol Cancer Ther; 2018 Apr; 17(4):838-848. PubMed ID: 29483215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma.
    Weng J; Liu S; Zhou Q; Xu W; Xu M; Gao D; Shen Y; Yi Y; Shi Y; Dong Q; Zhou C; Ren N
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37385725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Holistic Evolutionary and 3D Pharmacophore Modelling Study Provides Insights into the Metabolism, Function, and Substrate Selectivity of the Human Monocarboxylate Transporter 4 (hMCT4).
    Papakonstantinou E; Vlachakis D; Thireou T; Vlachoyiannopoulos PG; Eliopoulos E
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.